Eun Yang (born 1973) is a Korean American weekend news anchor and general assignment reporter during the week for NBC4/WRC-TV, the local NBC television ...
Googleplus
Eun Yang
Eun Yang
Eun Yang
Eun Yang
Eun Yang
Youtube
News4 Celebrates Eun Yang's 20th Anniversary ...
News4 is celebrating anchor Eun Yang, who's been #Working4You for 20 y...
Duration:
2m 55s
MoCos Most Famous: NBC4 News Anchor Eun Yang
News anchor/reporter Eun Yang has covered popes, inaugurations and eve...
Duration:
12m 56s
Prix de Lausanne 2008 - Chae Eun Yang - Class...
Prix de Lausanne 2008 - Chae Eun Yang - Classical Variation.
Duration:
1m 42s
Eun Yang from NBC Washington Nonstop visits 2...
Join Chef Bertrand Chemel and Eun Yang from NBC Washington Nonstop Foo...
Duration:
33m 2s
Welcome by Carla Hayden & Eun Yang: 2021 Nati...
Librarian of Congress Carla Hayden and News4 Today journalist Eun Yang...
Duration:
3m 56s
Eun Yang & the Importance of the National Par...
WRC-TV NBC4 anchor and event emcee Eun Yang discusses why the work of ...
SPOTTED: Rep.-elect Elissa Slotkin (D-Mich.) and David Moore, Debbie James, Gordon Tanner, Adam Topper, Stuart Spencer, Gautam Raghavan, Bishop Gene Robinson, Eun Yang, Jim Obergefell, Amy Dacey, Alex Wagner, Mike Sozan, Melissa Fitzgerald and Flo Groberg.
Date: Jan 02, 2019
Category: Headlines
Source: Google
Alexion snags longtime Biogen vet and 'careful steward' Clancy to fill its CFO post
billion Synageva buyout, has also been struggling mightily, and at Tuesdays Goldman Sachs Healthcare Conference, Hantson assured investors that future M&A would be very disciplined so as to avoid another Kanuma-like situation, Jefferies analyst Eun Yang wrote in a note to clients.
Still, the PFS improvement of 8.7 months is encouraging, wrote Jefferies analyst Eun Yang in an investor note today, adding that she had expected at least six months. PFS improvement of ~8-9 mo could lead to potential OS benefits per our prior expert discussion. This would likely secure label exp
Date: Aug 04, 2014
Category: Health
Source: Google
A preview, stats and tips for this week's closing leg of the Desert Swing - the ...
THE ANALYSIS: Jefferies & Co. analyst Eun Yang said the disclosure about tumors was "quite surprising." She said Kynamro probably won't be approved, and if it is, its market approval will probably be tightly limited because of the side effects and the large proportions of patients who dropped ou
Date: Oct 16, 2012
Category: Health
Source: Google
Prolia, Xgeva fall short of analysts' Q3 sales forecasts
At the current denosumab sales run-rate, we maintain our below-guidance/consensus total denosumab sales estimate of $2.085B for 2015 (vs. AMGN's guidance of $3B-$4B and consensus of $2.93B), said Jefferies analyst Eun Yang in an investor note issued this evening.
Date: Oct 25, 2011
Category: Business
Source: Google
Ahead of the Bell: Optimer rises on FDA panel vote
Jefferies & Co. analyst Eun Yang said it's not a guarantee the FDA will approve the drug on May 30. The panel found Dificid was safe and effective, and panelists voted that it was more effective than the drug Vancocin in preventing recurrent infections. But she said the FDA and Optimer may need